Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company developing bifunctional therapies for patients with solid tumors. The company’s lead program, ficerafusp alfa (formerly BCA101), is a bifunctional antibody that combines an epidermal growth factor receptor (EGFR)-directed monoclonal antibody with a transforming growth factor beta (TGF-β) ligand trap. This design delivers tumor-modulating payloads directly to the tumor microenvironment to enhance drug exposure and limit systemic toxicity. The company is currently evaluating ficerafusp alfa in clinical trials for head and neck squamous cell carcinoma (HNSCC), specifically in combination with pembrolizumab for first-line recurrent or metastatic, HPV-negative HNSCC. The ongoing FORTIFI-HN01 Phase 2/3 trial is designed to support potential accelerated approval based on overall response rate and durability. Bicara Therapeutics focuses on tumor types with strong biologic rationale for dual inhibition of EGFR and TGF-β pathways, including other squamous cell carcinomas where these targets are overexpressed.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage bicara.com
Sector Healthcare IR page ir.bicara.com
Tags
oncology, solid tumors, bifunctional antibodies, egfr, tgf-beta, head and neck cancer, squamous cell carcinoma, tumor microenvironment, immunotherapy, clinical-stage, ficerafusp alfa, BCA101, FORTIFI-HN01
Press page —

Metrics

Valuation  
Market cap $ 1.235B
Market cap (USD) $ 1.235B
P/E -5.38
PEG —
P/BV 3.02
P/S —
P/OCF -7.64
P/FCF -7.59
Dividend yield —
Turnover / mcap —
Returns  
ROE -30.9%
ROI -45.2%
ROIC -38.2%
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 26
Quality score -75.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022
Assets 430.994M 509.996M 233.982M 6.703M
Net profit -137.95M -67.995M -51.985M -37.845M
Free cash flow -107.114M -74.822M -46.214M -32.268M

Figure FY 2025 FY 2024 FY 2023 FY 2022
Share price 16.83 17.42 — —
Price performance 12m -0.03 — — —

Filed figures

Figure Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — 657,000 738,000 1.71M
Cash and deposits (USD) 4.16M 230M 490M 96.7M
Right-of-use assets (USD) — 613,000 690,000 1.7M
Cash flow detail
Operating cash flow (USD) — -45.6M -74.8M -107M
Purchases of property, plant and equipment (USD) — -586,000 -71,000 -280,000
Share-based compensation (USD) — 1.9M 7.4M 15M
Free cash flow (OCF - PPE - intangibles) (USD) — -46.2M -74.8M -107M
Income detail
Research and development expense (USD) — 30.6M 63.6M —
Total comprehensive income (USD) — — -68M -138M
Comprehensive income to owners (USD) — — -68M -138M
Reported Nov 12, 2024 Mar 27, 2025 Mar 30, 2026 Mar 30, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Achieved substantial enrollment in FORTIFI-HN01 pivotal trial in 1L R/M HPV-negative HNSCC; topline results from interim analysis expected in mid-2027

Enrolling FORTIFI-FLEX alternate dosing study; expect to have data by the time of potential U.S. approval in 1L R/M HPV-negative HNSCC

Company to host conference call and webcast today, November 9, 2026 at 8:30 a.m. ET

BOSTON, November 9, 2026 – Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced financial results for the third quarter ended September 30, 2026 and provided a business update.

“Ficerafusp alfa was purpose-built for HPV-negative head and neck cancer by inhibiting both EGFR and TGF-β, and the depth and durability of response it has demonstrated to date continue to set it apart in a disease with significant unmet need,” said Ryan Cohlhepp, President, Interim Chief Executive Officer and Chief Operating Officer of Bicara Therapeutics.

Nov 4, 2026

PDF Version

BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded an inducement grant on November 2, 2026, to one new employee as a material inducement to employment under Bicara’s 2026 Inducement Plan.

The employee received a non-qualified stock option to purchase 50,000 shares of Bicara’s common stock, par value $0.0001 per share, with an exercise price of $7.93 per share, equal to the closing price of Bicara’s common stock as reported by Nasdaq on November 2, 2026. One-fourth of the options vest on the first anniversary of the employee’s applicable start date, with the remaining options vesting in 12 equal quarterly installments thereafter, subject to the employee’s continued service with the company through each applicable vesting date.

The above award was granted outside of Bicara’s stockholder-approved equity incentive plans and is pursuant to Bicara’s 2026 Inducement Plan, which was adopted by Bicara’s board of directors in January 2026. The award was approved by the compensation committee of Bicara’s board of directors, which is comprised solely of independent directors, as a material inducement to the employee entering into employment with Bicara in accordance with Nasdaq Listing Rule 5635(c)(4).

About Bicara Therapeutics Bicara is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara has built a platform designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site. This approach was deployed in the development of Bicara’s lead program ficerafusp alfa, formerly BCA101, a bifunctional epidermal growth factor receptor (EGFR) directed monoclonal antibody bound to a human transforming growth factor beta (TGF-β) ligand trap. By combining these two clinically validated targets, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation, as well as the immunosuppressive TGF-β signaling within the tumor microenvironment (TME). Ficerafusp alfa directs the TGF-β inhibitor into the immediate TME through the binding of EGFR on tumor cells, which Bicara believes will lead to deep and durable responses and an increase in overall survival, while reducing the potential adverse effects previously associated with systemic TGF-β inhibition. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types. For more information, please visit www.bicara.com or follow us on LinkedIn and X.

Nov 2, 2026

PDF Version

BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that it will report third quarter 2026 financial results and business updates before the market opens on Monday, November 9, 2026. Bicara will host a conference call to discuss the financial results and business updates at 8:30 a.m. ET the same day. Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and a unique PIN that will allow them to access the call. To access the live webcast, please visit the “Events & Presentations” section within the Investors page on the Bicara website. A replay of the webcast will be available for 30 days following the event.

About Bicara Therapeutics Bicara is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara has built a platform designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site. This approach was deployed in the development of Bicara’s lead program ficerafusp alfa, formerly BCA101, a bifunctional epidermal growth factor receptor (EGFR) directed monoclonal antibody bound to a human transforming growth factor beta (TGF-β) ligand trap. By combining these two clinically validated targets, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation, as well as the immunosuppressive TGF-β signaling within the tumor microenvironment (TME). Ficerafusp alfa directs the TGF-β inhibitor into the immediate TME through the binding of EGFR on tumor cells, which Bicara believes will lead to deep and durable responses and an increase in overall survival, while reducing the potential adverse effects previously associated with systemic TGF-β inhibition. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types. For more information, please visit www.bicara.com or follow us on LinkedIn and X.

Prompts

Bicara Therapeutics Inc. (ticker BCAX), listed in United States.

ETFs Holding Bicara Therapeutics Inc.

ETF Weight in ETF Shares Market value As of
TMED 0.53% 4,103 $ 121.818K Jun 30, 2026
CANC 0.41% 37,499 $ 866.977K Aug 31, 2026
WCEO 0.17% 628 $ 17.019K Jul 31, 2026
FESM 0.07% 145,399 $ 4.317M Jun 30, 2026
TMSL 0.06% 52,318 $ 1.553M Jun 30, 2026
FSEG 0.05% 92 $ 2,731.48 Jun 30, 2026
VFMO 0.04% 33,515 $ 774.867K Aug 31, 2026
RESM 0.04% 44 $ 1,306.36 Jun 30, 2026
AVSC 0.03% 87,951 $ 857.522K Nov 16, 2026
MSSM 0.01% 2,562 $ 59.233K Aug 31, 2026
DFAS 0.01% 262,355 $ 2.652M Nov 12, 2026
DXUV 0.00% 24,670 $ 249.414K Nov 12, 2026
DCOR 0.00% 63,217 $ 639.124K Nov 12, 2026
DFAU 0.00% 15,152 $ 153.187K Nov 12, 2026
DFAC 0.00% 94,965 $ 960.096K Nov 12, 2026
DFUS 0.00% 10,728 $ 108.46K Nov 12, 2026
AVUS 0.00% 12,680 $ 123.63K Nov 16, 2026